WATERTOWN, Mass.--(Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that Tetraphase President & Chief Executive Officer Guy Macdonald is scheduled to present at the following conferences in September and October:)--
- The annual UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 3:00 p.m. Eastern time at The Grand Hyatt, New York, New York
- BioPharm America™ 2012 on Friday, September 21, 2012 at 8:45 a.m. Eastern time at The Westin Boston Waterfront Hotel, Boston, Massachusetts
- The 11th Annual BIO Investor Forum, which will be held from October 9-10, 2012 at The Palace Hotel, San Francisco, California
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. To learn more about Tetraphase, please visit www.tphase.com.